Abstract
We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to day +14 or to discharge. All patients were assessed for clinical status, mucositis, blood counts, oral intake and immune reconstitution. Parenteral nutrition was administered according to predefined guidelines. Forty patients were randomized; 21 into the glutamine and 19 into the placebo arm. Glutamine patients had less days with diarrhoea (3.3 ± 4.0 vs4.3 ± 3.0, P = 0.03), but they had more severe oral mucositis (mean 4 ± 4.7 vs 1.4 ± 2.3 days of mucositis score >13, P = 0.04), spent more days on opioids (mean 3.5 ± 4.2 vs 1.2 ± 2.2 days, P = 0.03) and left hospital later than placebo patients (mean 13.5 ± 3.1 vs 11.7 ± 2.4 days after transplant, P = 0.06). There were more relapses (P = 0.02) and deaths (P = 0.05) in the glutamine group. The cost of supportive care (mean 2960 ± 1694 vs 1534 ± 513 Euro, P = 0.002) was also greater for glutamine patients, mainly due to the cost of glutamine dipeptide itself. The described mode and dosage of glutamine administration did not produce meaningful benefit in our autologous transplant patients and it was certainly not cost-effective.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fox AD, Kripke SA, Depaula J et al. Effect of a glutamine supplemented enteral diet on methotrexate-induced entorecolitis J Parent Enteral Nutr 1988 12: 325 331
Anderson PM, Schroeder G, Skubitz MD . Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy Cancer 1998 83: 1433 1439
Jebb SA, Osborne RJ, Maughn TS . 5-Fluorouracil and folinic acid-linduced mucositis: no effect of glutamine supplementation Br J Cancer 1994 70: 732 735
van Zannen HCT, van der Leilie H, Timmer JG et al. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity Cancer 1994 74: 2879 2884
Ziegler TR, Young L, Benfell K et al. Clinical and metabolic efficacy of glutamine supplemented parenteral nutrition after bone marrow transplantation Ann Intern Med 1992 116: 821 828
Ziegler TR, Bye RL, Persinger RL et al. Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation Am J Med Sci 1998 315: 4 10
Schloerb P, Amare M . Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical application J Parent Ent Nutr 1993 17: 407 413
Anderson PM, Ramsay NKC, Shu XO et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation Bone Marrow Transplant 1998 22: 339 344
Tamada H, Nezu R, Matsuo Y et al. Alanyl-glutamine enriched TPN restores intestinal adaptation after either proximal or distal massive resection in rats J Parent Ent Nutr 1993 17: 348 354
Inoue Y, Grant J, Snyder PH . Effect of glutamine-supplemented total parenteral nutrition on recovery of the small intestine after starvation atrophy J Parent Ent Nutr 1993 17: 165 170
A randomized phase III trial of sequential high dose chemotherapy or standard chemotherapy for optimally debulked FIGO stage III and IV ovarian cancer An EBMT study, Amendment 2 8 July 1999 (Study protocol)
Rapoport AP, Miller Watelet LF, Linder T et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants J Clin Oncol 1999 17: 2446 2453
Kraut JR, Lloyd-Still JD . The 1-hr blood xylose test in the evaluation of malabsorption in infants and children Am J Clin Nutr 1980 33: 2328 2333
Bow EJ, Loewen R, Gehang MS et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults J Clin Oncol, 1997 15: 2254 2261
Houdijk APJ, Rijnsburger ER, Jansen J et al. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma Lancet 1998 352: 772 776
Walker AM . Low power and striking results – a surprise but not a paradox New Engl J Med 1995 332: 1091 1092
Schloerb PR, Skikne BS . Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study J Parent Ent Nutr 1999 23: 117 122
Coghlin Dickson TM, Wong RM, Offrin RS et al. Effect of oral glutamine supplementation during bone marrow transplantation J Parent Enteral Nutr 2000 24: 61 66
Collins R, MacMahon S . Reliable assessment of the effect of treatment on mortality and major morbidity, I: clinical trials Lancet 2001 357: 373 380
Decker-Baumann C, Buhl K, Frohmuller S et al. Reduction of chemotherapy-induced side effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer Eur J Cancer 1999 35: 202 207
Huang EY, Leung SW, Wang CJ et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial Int J Radiat Oncol Biol Phys 2000 46: 535 539
Daniele B, Perrone F, Gallo C et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled randomised trial Gut 2001 48: 28 33
Vahdat L, Papadopoulos K, Lange D et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine Clin Cancer Res 2001 7: 1192 1197
Feldman AM, Bristow MR, Parmley WW et al. Effect of vesnarinone on morbidity and mortality in patients with heart failure New Engl J Med 1993 329: 149 155
Cogh JN, Goldstein SO, Greenberg BH et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure New Engl J Med 1998 339: 1810 1816
Cockerham MB, Weinberger BB, Lerchie SB . Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation Ann Pharmacother 2000 34: 300 303
Canovas G, Leßn-Sanz M, Gómez P et al. Oral glutamine supplements in autologous hematopoietic transplant: impact on gastrointestinal toxicity and plasma protein levels Haematologica 2000 85: 1229 1230
Acknowledgements
Thanks to Ms Jana Kovarikova and Ms Jana Potockova for administrative help. Special thanks to Dr Peter RE Johnson for critical review of the manuscript. This study was supported by the grant IGA 5502/3 of Czech Ministry of Public Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pytlík, R., Beneš, P., Patorková, M. et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant 30, 953–961 (2002). https://doi.org/10.1038/sj.bmt.1703759
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703759
Keywords
This article is cited by
-
Pathogenesis and Amelioration of Radiation-Induced Oral Mucositis
Current Treatment Options in Oncology (2022)
-
MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients
Supportive Care in Cancer (2021)
-
A systematic review of interventions to mitigate radiotherapy-induced oral mucositis in head and neck cancer patients
Supportive Care in Cancer (2021)
-
Integrative Approaches to Chemotherapy-Induced Peripheral Neuropathy
Current Oncology Reports (2020)
-
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements
Supportive Care in Cancer (2019)